Table 3.
Systolic blood pressure variability and spontaneous baroreceptor sensitivity prior to (baseline) and after inhalation of the study drugs (T5, T15, T30, T90)
| Salbutamol | Placebo | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | T5 | T15 | T30 | T90 | T5 | T15 | T30 | T90 | |
| LFnu-SBPV | 40 ± 12 | 45 ± 13 | 45 ± 13 | 44 ± 10 | 39 ± 9 | 45 ± 14 | 42 ± 14 | 42 ± 14 | 40 ± 13 |
| LF-SBPV, ms2 | 5.9 ± 6.9 | 3.7 ± 2.4 | 2.9 ± 1.8 | 2.5 ± 1.5 | 4.6 ± 4.2 | 4.8 ± 3.3 | 3.8 ± 2.4 | 3.1 ± 1.7 | 5.5 ± 5.2 |
| HFnu-SBPV | 13 ± 14 | 12 ± 11 | 12 ± 10 | 12 ± 9 | 11 ± 5 | 11 ± 6 | 11 ± 6 | 12 ± 6 | 14 ± 6 |
| HF-SBPV, ms2 | 1.6 ± 2.1 | 0.9 ± 0.8 | 0.7 ± 0.7 | 0.6 ± 0.5 | 1.0 ± 0.8 | 1.2 ± 1.0 | 1.1 ± 0.9 | 1.0 ± 0.8 | 1.6 ± 1.0 |
| LF/HF-SBPV | 5.5 ± 4.2 | 6.0 ± 4.0 | 5.9 ± 4.7 | 6.1 ± 5.0 | 4.8 ± 2.9 | 5.2 ± 2.9 | 4.8 ± 2.5 | 4.2 ± 2.3 | 3.3 ± 1.5 |
| PI+/SBP+ | 26 ± 14 | 21 ± 13 | 30 ± 16 | 29 ± 16 | 32 ± 22 | 39 ± 41 | 36 ± 22 | 42 ± 26 | 41 ± 30 |
| PI−/SBP− | 31 ± 14 | 25 ± 11 | 23 ± 13 | 23 ± 13 | 30 ± 25 | 36 ± 22 | 31 ± 20 | 36 ± 24 | 33 ± 22 |
LF-SBPV and HF-SBPV, low-frequency and high-frequency systolic blood pressure variability expressed as normalized units (nu) or absolute values (ms2); PI+/SBP+, PI−/SBP−, sequences of consecutive beats in which progressive increases in SBP of at least 1 mmHg beat−1 for at least three consecutive heart beats are followed by a progressive lengthening in pulse interval (PI) of at least 4 ms beat−1 (PI+/SBP+ sequences) or, vice versa, progressive decreases in SBP are followed by a progressive shortening in PI (PI−/SBP− sequences).